Anne L. Angiolillo, M.D., is an attending physician in the Center for Cancer and Blood Disorders at Children’s National Hospital in Washington, D.C. and a professor of pediatrics at the George Washington University School of Medicine and Health Sciences. At Children's National, she is Director of the Leukemia and Lymphoma Program. She is an active member in the Children’s Oncology Group (COG), the largest clinical research consortium for pediatric cancer research.
Over the course of her twenty-five years as a pediatric oncologist, Dr. Angiolillo has treated children with leukemia and lymphoma and her research has had a significant impact on treatment advancements. Dr. Angiolillo has served as Children's National's Principal Investigator (PI) for the COG Phase I Consortium from 2001 to 2015 examining the use of novel agents in children with relapsed disease.
She has served as Vice Chair of CCG-09717, “A Phase I Study of Thrombopoietin (rhTPO) plus GCSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors” and COG-ADVL0013, “A Phase I Study of Yttrium-Ibritumomab Tiuxetan (IDEC-Y2B8, Yttrium (90)-Anti-Anti-CD20 Preceded by Rituximab (IDEC-C2B8) in Children with Recurrent/Refractory CD20 Positive Lymphoma.” She was Children's National PI for Bristol-Myers Squibb’s Protocol, “A Phase I Study of Carboplatin and Irinotecan in Patients 1 – 21 Years of Age with Refractory Solid Tumors.”
Dr. Angiolillo chaired COG-ADVL0022, “A Phase II Study of Gemcitabine in Children with Relapsed Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia” and for COG- ADVL0222, “A Phase II Study of Campath-1 H in Children with Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure.” Dr. Angiolillo was a Committee member of COG ADVL0524, “Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults with Refractory Solid Tumors.” Combined, these studies have advanced the field.
Recently, Dr. Angiolillo served as Study Chair for COG AALL07P4, “A Pilot Study of Intravenous EZN-2285 (SC-PEG E. coli L-asparaginase, IND# 100594; ASPARLAS) or Intravenous Oncaspar in the Treatment of Patients with High Risk Acute Lymphoblastic Leukemia.” Her work was pivotal to the recent FDA approval of ASPARLAS, an alternative to Oncaspar with improved biological properties. ASPARLAS is now approved as a component of a multi agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patient’s age 1 month to 21 years, potentially having a major impact globally.
She also served as Chair of COG AALL0932, “Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).” The results of AALL0932 have become available and have demonstrated outstanding outcomes.